KDC-MN-361 – Kodiac biolabs

Plain-language summaryIntrigue 50 / 100

Domagrozumab (PF-06252616) is Pfizer’s second-generation anti-myostatin antibody, designed for higher affinity than stamulumab. The pivotal phase 2 trial in Duchenne muscular dystrophy (2018) showed meaningful muscle mass increases on MRI but failed to demonstrate functional benefit on the primary motor outcome, leading Pfizer to terminate the program. The pattern (muscle mass without function) has now repeated across nearly every anti-myostatin compound tested in muscular dystrophy and is the central puzzle of the field: blocking myostatin reliably grows muscle but does not seem to make patients meaningfully stronger. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

32/100

Failed DMD phase 2 retained as a selective myostatin probe for mechanistic research

Look, the anti-myostatin story has not gone well for anyone. Wyeth’s stamulumab, Lilly’s landogrozumab, Regeneron’s trevogrumab – the list of humanized antibodies that neutralized myostatin beautifully in animals and then failed in humans is long enough now that we have to take the lesson seriously. Domagrozumab is the Pfizer entry in that cohort, and its 2018 phase 2 in DMD produced the most clinically instructive kind of failure: muscle mass went up on MRI, but the 6-minute walk test and North Star Ambulatory Assessment didn’t move.

That result isnt just a dead end – its actually the most scientifically interesting thing about this compound. It suggests the limiting factor in DMD isnt myostatin-mediated mass suppression; its the relentless mechanical damage from dystrophin deficiency. You can add muscle, and the dystrophic fiber still breaks down faster than myostatin inhibition can compensate. Thats genuinely clarifying biology, and domagrozumab helped establish it.

The novelty problem is real. Myostatin inhibition as a concept is nearly thirty years old – the McPherron double-muscle mouse dates to 1997. The IgG1 antibody approach to neutralizing GDF-8 is well-trodden at this point, and domagrozumab doesnt have a mechanism angle that distinguishes it meaningfully from the compounds that came before. Its not doing anything the class hadn’t already tried, and the mechanism score reflects that: single-receptor neutralization in a saturated, largely-failed class.

Differentiation is the weakest score here. Against other anti-myostatin antibodies, domagrozumab occupies no particular best-in-class position. Its affinity for myostatin is high, it’s humanized, its PK in humans is characterized – that makes it a functional research tool, but not a leading one. We think the ActRII-pathway inhibitors (luspatercept, bimagrumab) are more interesting if you want to study muscle anabolism broadly, because they engage the wider TGF-beta ligandome and produce cleaner clinical signals.

What domagrozumab does retain is probe value for investigators who specifically want myostatin-selective inhibition, as opposed to the broader ligand traps that catch activin, GDF-11, and other TGF-beta family members alongside GDF-8. If your question is specifically about GDF-8 rather than the whole ActRIIB ligandome, this compound gives you a cleaner experimental handle. Thats a narrow utility but its real.

The phase 2 evidence is actually quality evidence – well-designed RCT, adequate N, prespecified functional endpoints – it just produced a negative answer. The evidence quality score is respectable for that reason. The translational signal, though, is genuinely negative: the mechanism did not translate to clinical benefit in the target population, and that distinction matters for how we weight this overall.

Bench scientists studying DMD pathophysiology, the myostatin signaling axis, or the dissociation between muscle mass and functional output in dystrophic tissue will find this a documented, human-characterized probe. For everyone else, the evidence has made the case for moving on.

Novelty: 28
Mechanism promise: 35
In-category differentiation: 20
Evidence quality: 50
Translational signal: 22
Research bench value: 48

Rationale Domagrozumab’s 2018 phase 2 in DMD decisively closed the clinical case: muscle mass increases on MRI did not translate to functional gains, and Pfizer walked away. Scores are suppressed by low novelty in a 25-year-old target class, no meaningful differentiation from other failed anti-myostatin antibodies, and a clearly negative translational signal; residual probe value for GDF-8-selective biology keeps bench_value from bottoming out.

Anti-myostatin monoclonal antibody

A humanized anti-myostatin monoclonal antibody developed at Pfizer for Duchenne muscular dystrophy; phase 2 trial failed.

Abstract

Domagrozumab (PF-06252616; humanized IgG1 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized anti-myostatin monoclonal antibody developed at Pfizer. The compound is selective for myostatin (GDF-8) with high affinity, designed to neutralize circulating myostatin in Duchenne muscular dystrophy. Phase 2 trial in DMD (2018) demonstrated muscle mass increases on MRI but no significant improvement in functional endpoints (6-minute walk test, North Star Ambulatory Assessment); Pfizer discontinued development. The trial result reinforced a broader concern about myostatin inhibition in DMD: muscle mass gains may not translate to clinical benefit if the underlying dystrophin deficiency continues to cause fiber damage. Used as a research compound for selective myostatin neutralization in DMD context.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-361Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-361

Domagrozumab

Abstract

Read the full monograph